Applied Research Systems Ars Holding N.V.
Records under this name other than patents Applied Research Systems Ars Holding N.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Applied Research Systems Ars Holding N.V.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,772,233 | Novel Arylamino N-Heteroaryl Compounds as Mek Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 7,956,191 | 3-Arylamino Pyridine Derivatives Formerly held In force · High confidence | In force | High confidence | |
| US 8,133,699 | Minimal DNA sequence acting as a chromatin insulator and its use in protein expression Formerly held In force Term ended Oct 16, 2026 · USPTO record | In force | Term ended Oct 16, 2026 | USPTO record |
| US 7,824,907 | Expression vectors comprising the mCMV IE2 promoter Formerly held Term ended Term ended May 30, 2026 · USPTO record | Term ended | Term ended May 30, 2026 | USPTO record |
| US 8,003,090 | Method for Inhibiting a Microvascular Complication by Administering IL-6 Formerly held Term ended Ended no later than Jan 9, 2026 · Medium confidence | Term ended | Ended no later than Jan 9, 2026 | Medium confidence |
| US 8,198,457 | 3-Arylamino Pyridine Derivatives Formerly held Term ended Term ended Oct 19, 2025 · High confidence | Term ended | Term ended Oct 19, 2025 | High confidence |
| US 8,841,459 | 3-Arylamino Pyridine Derivatives Formerly held Term ended Term ended Oct 19, 2025 · High confidence | Term ended | Term ended Oct 19, 2025 | High confidence |
| US 8,524,911 | 3-Arylamino Pyridine Derivatives Formerly held Lapsed on the fee record Ended Sep 3, 2025 · High confidence | Lapsed on the fee record | Ended Sep 3, 2025 | High confidence |
| US 9,592,267 | Use of IL-18BP for treatment of peripheral vascular diseases Formerly held Term ended Term ended May 4, 2025 · Medium confidence | Term ended | Term ended May 4, 2025 | Medium confidence |
| US 9,051,582 | Expression vectors comprising the mCMV IE2 promoter Formerly held Term ended Term ended Feb 28, 2025 · USPTO record | Term ended | Term ended Feb 28, 2025 | USPTO record |